Raloxifene Mitigates Emotional Deficits after Mild Traumatic Brain Injury in Mice
Department of Anatomy and Neurobiology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Department of Ophthalmology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Abstract
Persons with mild traumatic brain injury (TBI) often exhibit persistent emotional impairments, particularly depression, fearfulness, and anxiety, that significantly diminish quality of life. Studying these mood disorders in animal models of mild TBI can help provide insight into possible therapies. We have previously reported that mice show increased depression, fearfulness, and anxiety, as well as visual and motor deficits, after focal cranial blast and that treatment with the cannabinoid type 2 receptor (CB2) inverse agonist, SMM-189, reduces these deficits. We have further shown that raloxifene, which is U.S. Food and Drug Administration approved as an estrogen receptor modulator to treat osteoporosis, but also possesses CB2 inverse agonism, yields a similar benefit for visual deficits in this model of TBI. Here, we have extended our studies of raloxifene benefit and show that it similarly reverses depression, fearfulness, and anxiety after focal cranial blast TBI in mice, using standard assays of these behavioral end-points. These results indicate the potential of raloxifene in the broad rescue of deficits after mild TBI and support phase 2 efficacy testing in human clinical trials.
Untitled section
Keywords: anxiety, CB2 inverse agonist therapy, depression, fear, raloxifene, traumatic brain injury
Article notes
Untitled section
Collection date 2022.
Introduction
Traumatic brain injury (TBI) is highly prevalent in the United States, with an estimated 3 million to 4 million persons affected each year. Falls and motor vehicle accidents are the most common causes, and explosive blast injury is an additional contributor for members of the military.1–4 The vast majority (>80%) of TBIs are classified as mild4,5 and, despite the absence of overt brain damage, often result in impaired cognitive, emotional, sensory, and motor function. For some persons, symptoms resolve within a few weeks, but for other persons, some symptoms, typically cognitive problems (e.g., difficulty concentrating, poor memory) and mood disorders (e.g., depression and anxiety), persist for a year or even longer.6–12 Exaggerated fearfulness is also common,13–15 and persons with these persistent symptoms suffer from a diminished quality of life. Despite the wide range of impairments that can ensue after mild TBI, treatments to intervene in the injury process and thereby stem the development and/or persistence of symptoms are currently lacking.
We have previously reported that mild TBI, produced by a high-pressure air blast to one side of the mouse head, causes visual, motor, and emotional deficits along with axonal degeneration and neuron loss.16–20 These are attenuated by treatment with the selective cannabinoid type 2 receptor (CB2) inverse agonist, SMM-189, which targets activated microglia and biases them away from the proinflammatory M1 state toward the protective M2 state.17,18,20,21 Further, the reduction in optic nerve axon loss is associated with the rescue of visual deficits and appears to stem from the modulatory effects of SMM-189 on activated microglia in the optic nerve and tract.20 SMM-189, however, has not been tested in humans, and so we have refocused our attention on evaluating the benefit provided by raloxifene. Raloxifene is approved by the U.S. Food and Drug Administration (FDA) because of its action as a selective estrogen receptor modulator (SERM), but also acts as a CB2 receptor inverse agonist.22,23
We have found that raloxifene mitigates visual deficits and the associated visual system pathology resulting from mild TBI produced by focal cranial blast,23 or by an impact to the dorsum of the head,24 and by direct ocular blast.25 Raloxifene effectiveness for numerous end-points with these injuries strongly encourages its consideration for repurposing to treat traumatic neural injury in the human population. Here, we extend our studies of raloxifene by examining whether it also lessens depression, fear, and anxiety after focal cranial blast. Our results demonstrate a raloxifene benefit for these emotional impairments and thereby support phase 2 trial efficacy testing in humans.
Methods
Animals and overall experimental plan
Male C57BL/6 mice at 8–10 weeks of age were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were subjected to TBI at 3–4 months of age, treated for 2 weeks, and later underwent behavioral assessments (Fig. 1A). Mice tested for anxiety corresponded to some of the animals for which we previously reported visual deficits.23 Other cohorts of mice were used to examine depression and fear. The numbers of mice per group for each experiment are provided in the relevant figure legends. Animal studies were performed in accordance with University of Tennessee Health Science Center Institutional Animal Care and Use Committee–approved and Department of Defense–approved protocols and complied with National Institutes of Health and Society for Neuroscience guidelines.
Blast traumatic brain injury device and blast administration
Our focal cranial blast model of mild TBI has been previously described in detail.19 In brief, mice were anesthetized with avertin (400 mg/kg, injected intraperitoneally [i.p.]) and inserted into protective tubing that shielded the animal, except for a 7.5-mm diameter area on the left side of the head (Fig. 1B). A single blast of 50 pounds per square inch (psi) above atmospheric pressure, which produces widespread axonal injury but no overt brain contusion,19,26 was delivered to the mouse head. Sham blast (0-psi) mice were handled in the same way, but with a metal plate blocking the blast wave from reaching the animal. After blast, mice were kept warm and recovered from anesthesia in 15–30 min. Acetaminophen was provided in drinking water at 1.6 mg/mL for 24 h before and after blast.
Raloxifene and vehicle administration
Raloxifene (Sigma-Aldrich, St. Louis, MO), diluted in vehicle containing ethanol/Cremophor/0.9% saline (5:5:90), was administered at a dose of 5 or 10 mg/kg of body weight, as in our past studies.23–25 Mice were injected i.p. with raloxifene or vehicle, beginning 2 h after blast, and again at approximately the same time every day (±1 h) for the next 14 days (15 doses in total). For brevity, mice that received blast and vehicle will be referred to as blast-vehicle, sham mice that received vehicle as sham-vehicle or simply sham, and mice that received blast and drug as blast-ral5 or blast-ral10, depending on the dose.
Tail suspension depression test
The tail suspension test was used to assess the characteristic of depression termed behavioral despair, as described in our past studies.16,17 Mice suspended by the tail eventually stop attempting to escape and become immobile, with a depressive-like state indicated by a longer duration of immobility compared to control animals. Each mouse was suspended by its tail and video recorded. Immobility was analyzed over a 5-min period using automated software (FreezeFrame; Coulbourn, Whitehall, PA).
Auditory fear conditioning
Fear responses were examined, as previously described,16,17,26 using a fear-conditioning chamber (Model ENV-008; MED Associates Inc., Fairfax, VT) and automated software (FreezeFrame; Coulbourn). Mice were acclimated to the chamber for 4 min and then received five training trials, each consisting of a 12-kH tone conditioned stimulus (CS) for 30 sec, coterminating with a 0.250-sec, 0.4-mA foot shock (unconditioned stimulus; US), with 3.5 min between trials. Mice were returned to the chamber the following day, and contextual fear was assessed for 3 min. This was followed by fifteen 20-sec presentations of the CS alone, with 2 min between presentation onsets, to evaluate retention of the conditioned fear. Contextual and conditioned fear responses were measured in 20-sec time blocks.
Light/dark box to assess anxiety
Rodent behavior in a light-dark box was first used to test the effectiveness of anxiolytics such as benzodiazepines.27,28 The basis of light-dark box testing is that rodents prefer dark, enclosed areas where they can hide, with more time spent in the dark compartment of the testing arena indicative of greater anxiety. As described previously,23 the light-dark box consisted of two equally sized compartments—an open chamber with clear walls and an enclosed chamber with black walls—connected by an opening. The test arena was covered by a black drape during the testing, to minimize outside distractions. The enclosed chamber contained a light bulb that could provide illumination at 500 or 1000 lux, and the illumination of the open chamber ranged from slightly >0 lux to a maximum of 8 lux when the enclosed chamber was at 1000 lux. Each test began with 5 min of no light in the enclosed chamber (0 lux), followed by 5 min of 500 lux and another 5 min of 1000 lux. Infrared laser beams detected the mouse location, and software measured time spent in each compartment. Given that mice are averse to bright light, they spend less time in the enclosed chamber as its illumination increases. More time spent in the enclosed arena compared to sham mice, particularly as the illumination increases, is indicative of heightened anxiety.
Statistical analysis
Data were analyzed with one-way analysis of variance (ANOVA), followed by post hoc comparisons, using SPSS software (SPSS, Inc., Chicago, IL). The specific corrections for multiple comparisons are provided in the figure legends.
Results
Tail suspension depression test
As in our past studies,16,17 mice subjected to focal cranial blast TBI showed a longer duration of immobility, indicative of increased depression, over the 5-min testing period compared to sham-vehicle mice (p = 0.0002; Fig. 2). The amount of immobility for blast-ral5 and blast-ral10 mice was significantly less than for blast-vehicle mice (p = 0.023 and p = 0.031, respectively) and nearly the same as in sham-vehicle mice. Thus, both doses of raloxifene rescued the depression-like state that is otherwise produced by focal cranial blast.
Auditory fear conditioning
Fear acquisition
The duration of freezing in response to the auditory CS increased progressively over the five training trials (Fig. 3A). Sham-vehicle and blast-vehicle mice did not differ significantly over the last three trials, consistent with our previous findings.16,17 Blast-ral10 mice behaved similarly. Thus, neither focal cranial blast nor treatment with 10 mg/kg of raloxifene altered fear acquisition. By contrast, freezing scores across the last three acquisition trials were significantly greater for blast-ral5 mice than sham-vehicle mice (p = 0.005), indicating that treatment with 5 mg/kg of raloxifene after focal cranial blast somehow enhanced fear learning.
Contextual fear
When mice were reintroduced to the testing chamber the day after fear acquisition, blast-vehicle mice exhibited significantly more freezing over the first three trial blocks (Fig. 3B) than sham-vehicle mice (p = 0.005), in accord with our previous results showing that contextual fear is enhanced after focal cranial blast.16,17 Freezing scores for blast-ral5 and blast-ral10 mice were significantly less than for blast-vehicle mice (p = 0.0003 and p = 0.0001, respectively) and not significantly different than for sham-vehicle mice. Thus, both raloxifene doses alleviated the increase in contextual fear produced by focal cranial blast.
Fear retention
The day after fear acquisition, blast-vehicle mice exhibited an increase in conditioned fear (Fig. 3C), in accord with our previous results.16,17 Freezing scores across the 15 trial blocks during CS presentation were significantly greater for blast-vehicle mice than for sham mice (p = 0.0002). Raloxifene at 10 mg/kg mitigated this increase, with freezing scores for blast-ral10 mice similar to those for sham-vehicle mice and somewhat, although not significantly, less than for blast-vehicle mice. By contrast, freezing scores for blast-ral5 mice were similar to those for blast-vehicle mice and significantly greater than for sham-vehicle mice (p = 0.007). Thus, 5 mg/kg of raloxifene did not prevent the increase in conditioned fear produced by focal cranial blast. It is uncertain whether the increased conditioned fear in blast-ral5 mice relative to sham mice stemmed from their increased fear acquisition and/or whether the lower raloxifene dose was insufficient to ameliorate the elevation in fear retention caused by focal cranial blast.
Anxiety in the light-dark arena
Sham-vehicle mice spent roughly equal amounts of time in the two chambers at the start of the testing session. They decreased their occupancy of the enclosed chamber as its illumination was increased (Fig. 4A), because of the aversiveness of the increasingly brighter lights. Blast-vehicle mice consistently spent a greater proportion of their time than sham-vehicle mice in the enclosed chamber at each of the three illumination levels, although the differences were not statistically significant. However, combining the data across illumination levels (Fig. 4B) revealed that blast-vehicle mice occupancy of the enclosed chamber was significantly greater than for sham-vehicle mice (p = 0.014), suggesting that blast-vehicle mice exhibit heightened anxiety. Occupancy of the enclosed chamber by blast-ral5 mice was significantly less than for blast-vehicle mice (p = 0.025) and similar to sham-vehicle mice, showing that 5 mg/kg of raloxifene reversed the increase in anxiety produced by focal cranial blast. Blast-ral10 mice did not differ significantly from sham-vehicle mice or blast-vehicle mice, suggesting that the higher raloxifene dose partially rescued the increase in anxiety.
Discussion
In the present study, we have extended our evidence for raloxifene benefit in mice after mild TBI produced by focal cranial blast from visual system deficits23 to emotional disorders. We show that mice exhibit depression, anxiety, and increased contextual and conditioned fear a few months after the injury and that raloxifene treatment reduces these behavioral impairments. Similar emotional abnormalities have been observed in rodents using other injury models29,30 and in humans who have experienced a mild TBI.6–15,31 Given that effective treatments to mitigate deficits after mild TBI are lacking, our findings support the notion that raloxifene could be repurposed for human use.
Mild traumatic brain injury
Numerous brain regions are involved in regulating mood, including pre-frontal, insular and anterior cingulate cortex, hippocampus, several amygdala subnuclei, nucleus accumbens, and the bed nucleus of the stria terminalis.11,32–35 The precise brain regions that cause depression, fear, and anxiety after mild TBI, and the nature of the alterations in them, are not well understood. Thus, determining how raloxifene acts on specific regions and cells within the brain to yield functional rescue, though desirable, is beyond the scope of the current study.
Mild TBI is characterized by widespread axonal injury.5,36,37 For our experimental model, focal cranial blast, damaged axons are abundant in white matter tracts after a few days19,20,23 and degenerating axons are visualizable after a few weeks.19 Such axonal injury may disturb communication between (and within) brain regions that regulate emotional state and thereby lead to a disordered mood.14,15 Neuronal loss18 and altered synaptic signaling ensuing from mild TBI may similarly disrupt communication between brain regions. The reduction in axon and neuron loss with raloxifene treatment,23 as well as the possible restoration of normal synaptic signaling, would then lessen the amount of disruption and thereby mitigate emotional deficits.
The axonal injury occurring after mild TBI sets off a series of secondary processes, one of the more prominent being microglial activation. The initial microglial responses are typically proinflammatory and, as such, cause further damage.38–41 We have, in fact, found activated microglia alongside damaged axons in white matter tracts19,20,23 and in some brain regions18,26 a few days after focal cranial blast, and increased expression of proinflammatory M1 markers.18,20,23 Consistent with a role of activated microglia, brain levels of proinflammatory cytokines are elevated in rodent models of depression, fear, and anxiety and with depression in humans.31,42–48 Thus, microglial activation in mood-regulating brain regions may contribute to progression of the injury after mild TBI and exacerbate the outcome. As an aside, it should be noted that our experimental approach does not cause contusive injury to the brain, and our previous morphological studies have not revealed any obvious macrophage invasion of the brain parenchyma.
Cannabinoid type 2 receptor inverse agonism
Microglia rapidly upregulate CB2 expression when neighboring cells are damaged, allowing drugs that bind CB2 receptors to specifically target microglia.40,49–52 CB2 inverse agonists stabilize CB2 receptors, which are otherwise constitutively active, in an inactive state, thereby biasing microglia away from the proinflammatory M1 state, toward the protective M2 state. CB2 inverse agonists thus derive their benefit from both types of actions.21,53,54 Our previous studies have demonstrated that the loss of optic nerve axons that otherwise ensues after focal cranial blast TBI is significantly reduced by 2 weeks of treatment with either raloxifene23 or the CB2 inverse agonist, SMM-189,20 suggesting that microglia can drive axonal degeneration.
In addition, SMM-189 mitigates abnormalities in oscillatory neuronal activity recorded from the hippocampus and pre-frontal cortex55 and rescues around half the neuron loss in cortex and striatum,18 supporting a role for microglia in these processes. More relevant to the work reported here, we have also shown that SMM-189 normalizes depression and contextual fear and diminishes conditioned fear after focal cranial blast.17 Further, SMM-189, the CB2 inverse agonist SR144528, and raloxifene yield a similar rescue of the contrast-sensitivity deficit produced by focal cranial blast, consistent with the idea that raloxifene rescue of visual deficits is attributable to effects on CB2 receptors.17,20,,23
Estrogenic effects of raloxifene
Although we have previously shown that raloxifene benefit for visual contrast sensitivity does not depend on its estrogenic effects23 and that raloxifene modulates microglia after brain and ocular injury,23–25 we cannot rule out the possibility that the rescue of emotional disorders reported here is partly, or entirely, attributable to raloxifene action at estrogen receptors. Estrogen is known to exert neuroprotective effects through multiple mechanisms, including inhibiting apoptosis and decreasing neuroinflammation.56 Estrogen receptors are expressed by microglia, neurons, and astrocytes in diverse brain regions, including the amygdala, pre-frontal cortex, and hippocampus.57 Raloxifene, like other SERMS, can elicit either agonist or antagonist effects at estrogen receptors, depending on the tissue, cell type, and context.58,59
Raloxifene dosing
An unresolved issue from the present study concerns differences in results for the two raloxifene doses. Raloxifene at 5 and 10 mg/kg provided similar benefit for depression and contextual fear, but the lower dose was better for anxiety, whereas the higher dose was better for conditioned fear. We previously observed dose differences in other functional and structural assessments and on the expression of M1- and M2-state microglial markers,23–25 suggesting that these may stem from variability in the extent and timing of microglial CB2 upregulation in different brain regions because of variation in severity of the injury in those regions. Regardless of the results in animal studies, optimizing the dosage, dosing frequency, and treatment window would be important components of any initial clinical testing. Although we typically administer raloxifene starting 2 h after injury, delaying treatment up until day 3 after focal cranial blast TBI is still effective,23 adding to the feasibility of raloxifene therapy. That a treatment period of only 2 weeks provides benefit for many of the end-points in the current and our previous studies23–25 suggests that a lengthy period of treatment would not be necessary.
Therapeutic implications for humans
An important drawback in beginning to assess the efficacy of SMM-189 and SR144528 for mild TBI in patients is that neither has undergone phase 1 safety trials. By contrast, given that raloxifene is already FDA approved, phase 2 clinical trials could start at any time. Raloxifene has been used since the late 1990s for treating post-menopausal osteoporosis. It can be taken orally, is also safe and effective in men, and has no evident adverse hormonal side effects.60–63 Interestingly, daily treatment with 120 mg of raloxifene (twice the dose used for osteoporosis) improves attention and memory in schizophrenic patients,63 indicating sufficient brain penetration for achieving benefit. Although we have administered raloxifene at yet higher doses, those doses are known to be safe in humans.58
We have previously demonstrated that raloxifene improves visual outcomes in mice after mild TBI produced by focal cranial blast,23 mild TBI produced by an impact to the head,24 and after ocular blast injury.25 Here, we expand upon our evidence for raloxifene benefit, showing that raloxifene reduces the depression, heightened fearfulness, and anxiety ensuing from focal cranial blast TBI. Given that mild TBI in humans often leads to a similar set of persistent, debilitating symptoms, a regimen of raloxifene delivered in the early aftermath of the injury may help reduce adverse emotional outcomes, as well as visual impairments. Taken together, our findings strongly support the consideration of raloxifene for treating mild TBI in humans.
Acknowledgments
Special thanks to Marion Joni and Desmond L. Henderson for technical assistance.
Abbreviations Used
- ANOVA
- analysis of variance
- CB2
- cannabinoid type 2 receptor
- CS
- conditioned stimulus
- FDA
- U.S. Food and Drug Administration
- i.p.
- intraperitoneally
- psi
- pounds per square inch
- SERM
- selective estrogen receptor modulator
- TBI
- traumatic brain injury
- US
- unconditioned stimulus
Data Availability
The data from this present study on raloxifene are available from the investigators upon reasonable request.
Funding Information
This work was supported by The University of Tennessee Neuroscience Institute (A.R.), the Office of the Dean of the College of Medicine at The University of Tennessee Health Science Center (A.R.), The Methodist Hospitals Endowed Professorship in Neuroscience (A.R.), and DoD grant W81XWH-16-1-0076 (A.R., M.G.H.).
Untitled section
Boxed Text
Cite this article as: Honig MG, Del Mar NA, Moore BM, et al. Raloxifene mitigates emotional deficits after mild traumatic brain injury in mice. Neurotrauma Reports 2022:3(1):534–544. doi: 10.1089/neur.2022.0052.
References
Untitled section
References
- 1. Mac Donald CL, Johnson AM, Wierzechowski L, et al. Prospectively assessed clinical outcomes in concussive blast vs nonblast traumatic brain injury among evacuated US military personnel. JAMA Neurol 2014;71(8):994–1002.
- 2. Centers for Disease Control and Prevention. Report to congress on traumatic brain injury in the United States: epidemiology and rehabilitation. National Center for Injury Prevention and Control; Division of Unintentional Injury Prevention: Atlanta, GA; 2015.
- 3. Taylor CA, Bell JM, Breiding MJ, et al. Traumatic brain injury-related emergency department visits, hospitalizations, and deaths—United States, 2007 and 2013. MMWR Surveill Summ 2017;66(9):1–16; doi: 10.15585/mmwr.ss6609a1
- 4. Dewan MC, Rattani A, Gupta S, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg 2018. doi: 10.3171/2017.10.JNS17352
- 5. Blennow K, Brody, DL, Kochanek PM, et al. Traumatic brain injuries. Nat Rev Dis Primers 2016;2:16084.
- 6. Cole WR, Bailie JM. Neurocognitive and Psychiatric Symptoms Following Mild Traumatic Brain Injury. In: Translational Research in Traumatic Brain Injury. (Laskowitz D, Grant G. eds.) CRC Press/Taylor and Francis Group: Boca Raton, FL; 2016; Chapter 19.
- 7. Dikmen S, Machamer J, Temkin N. Mild traumatic brain injury: longitudinal study of cognition, functional status, and post-traumatic symptoms. J Neurotrauma 2017;34(8):1524–1530; doi: 10.1089/neu.2016.4618
- 8. Ouellet MC, Beaulieu-Bonneau S, Sirois MJ, et al. Depression in the first year after traumatic brain injury. J Neurotrauma 2018;35(14):1620–1629; doi: 10.1089/neu.2017.5379
- 9. Hellewell SC, Beaton CS, Welton T, et al. Characterizing the risk of depression following mild traumatic brain injury: a meta-analysis of the literature comparing chronic mTBI to non-mTBI populations. Front Neurol 2020;11:350.
- 10. Machamer J, Temkin N, Dikmen S, et al. ; TRACK-TBI Investigators. Symptom frequency and persistence in the first year after traumatic brain injury: a TRACK-TBI study. J Neurotrauma 2022;39(5–6):358–370; doi: 10.1089/neu.2021.0348
- 11. Medeiros GC, Twose C, Weller A, et al. Neuroimaging correlates of depression after traumatic brain injury: a systematic review. J Neurotrauma 2022;39(11–12):755–772; doi: 10.1089/neu.2021.0374
- 12. Phipps H, Mondello S, Wilson A, et al. Characteristics and impact of U.S. military blast-related mild traumatic brain injury: a systematic review. Front Neurol 2020;11:559318.
- 13. Stein MB, McAllister TW. Exploring the convergence of posttraumatic stress disorder and mild traumatic brain injury. Am J Psychiatry 2009;166(7):768–776.
- 14. Kaplan GB, Leite-Morris KA, Wang L, et al. Pathophysiological bases of comorbidity: traumatic brain injury and post-traumatic stress disorder. J Neurotrauma 2018;35(2):210–225; doi: 10.1089/neu.2016.4953
- 15. Gordon EM, Scheibel RS, Zambrano-Vazquez L, et al. High-fidelity measures of whole-brain functional connectivity and white matter integrity mediate relationships between traumatic brain injury and post-traumatic stress disorder symptoms. J Neurotrauma 2018;35(5):767–779; doi: 10.1089/neu.2017.5428
- 16. Heldt SA, Elberger AJ, Deng Y, et al. A novel closed-head model of mild traumatic brain injury caused by primary overpressure blast to the cranium produces sustained emotional deficits in mice. Front Neurol 2014;5:2.
- 17. Reiner A, Heldt SA, Presley CS, et al. Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci 2015;16:758–787.
- 18. Bu W, Ren H, Deng Y, et al. Mild traumatic brain injury produces neuron loss that can be rescued by modulating microglial activation using a CB2 receptor inverse agonist. Front Neurosci 2016;10:449.
- 19. Guley NH, Rogers J, Del Mar N, et al. A novel closed-head model of mild traumatic brain injury using focal primary overpressure blast to the cranium in mice. J Neurotrauma 2016;33:403–422; doi: 10.1089/neu.2015.3886
- 20. Guley NM, Del Mar NA, Ragsdale T, et al. Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189. Exp Eye Res 2019;182:109–124.
- 21. Presley C, Abidi A, Suryawanshi S, et al. Pre-clinical evaluation of SMM-189, a cannabinoid receptor-2 specific inverse agonist. Pharmacol Res Perspect 2015;3:e00159.
- 22. Kumar P, Song ZH. Identification of raloxifene as a novel CB2 inverse agonist. Biochem Biophys Res Comm 2013;435:76–81.
- 23. Honig MG, Del Mar NA, Henderson DL, et al. Amelioration of visual deficits and visual system pathology after mild TBI via the cannabinoid type-2 receptor inverse agonism of raloxifene. Exp Neurol 2019;322:13063.
- 24. Honig MG, Del Mar NA, Henderson DL, et al. Raloxifene modulates microglia and rescues visual deficits and pathology after impact traumatic brain injury. Front Neurosci 2021;15:701317.
- 25. Honig MG, Del Mar NA, Henderson DL, et al. Raloxifene, a cannabinoid type-2 receptor inverse agonist, modulates microglia and rescues visual deficits and pathology after ocular blast. Exp Eye Res 2022;218:108966.
- 26. Honig MG, Dorian CC, Worthen JD, et al. Progressive long-term spatial memory loss following repeat concussive and subconcussive brain injury in mice, associated with dorsal hippocampal neuron loss, microglial phenotype shift, and vascular abnormalities. Eur J Neurosci 2021;54:5844–5979.
- 27. Crawley JN. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 1981;15(5):695–699.
- 28. Bourin M, Hascoët M.. The mouse light/dark box test Eur J Pharmacol 2003;463(1-3):55–65.
- 29. Semple BD, Zamani A, Rayner G, et al. Affective, neurocognitive and psychosocial disorders associated with traumatic brain injury and post-traumatic epilepsy. Neurobiol Dis 2019;123:27–41.
- 30. Shultz SR, McDonald SJ, Corrigan F, et al. The clinical relevance of behavior testing in animal models of traumatic brain injury. J Neurotrauma 2020;37(22):2381–2400; doi: 10.1089/neu.2018.6149
- 31. Bodnar CN, Morganti JM, Bachstetter AD. Depression following a traumatic brain injury: uncovering cytokine dysregulation as a pathogenic mechanism. Neural Regen Res 2018;13(10):1693–1704.
- 32. Ahrens S, Wu MV, Furlan A, et al. A central extended amygdala circuit that modulates anxiety. J Neurosci 2018;38(24):5567–5583.
- 33. Maddox SA, Hartmann J, Ross RA, et al. Deconstructing the gestalt: mechanisms of fear, threat and trauma memory encoding. Neuron 2019;102(1):60–74.
- 34. Biselli T, Lange SS, Sablottny L, et al. Optogenetic and chemogenetic insights into the neurocircuitry of depression-like behaviour: a systematic review. Eur J Neurosci 2021;53(1):9–38; doi: 10.1111/ejn.14603
- 35. Ressler KJ, Berretta S, Bolshakov VY, et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat Rev Neurol 2022;18(5):273–288.
- 36. Namjoshi DR, Good C, Cheng WH, et al. Towards clinical management of traumatic brain injury: a review of models and mechanisms from a biomechanical perspective. Dis Model Mech 2013;6:1325–1338.
- 37. Smith DH, Hicks R, Povlishock JT. Therapy development for diffuse axonal injury. J Neurotrauma 2013;30:307–323; doi: 10.1089/neu.2012.2825
- 38. Loane DJ, Kumar A. Microglia in the TBI brain: the good, the bad, and the dysregulated. Exp Neurol 2016;275 Pt 3(0 3):316–327; doi: 10.1016/j.expneurol.2015.08.018
- 39. Donat CK, Scott G, Gentleman SM, et al. Microglial activation in traumatic brain injury. Front Aging Neurosci 2017;9:208.
- 40. Komorowska-Müller JA, Schmöle AC. CB2 receptor in microglia: the guardian of self-control. Int J Mol Sci 2021;22(1):19; doi: 10.3390/ijms22010019
- 41. Mesquida-Veny F, Del Río JA, Hervera A. Macrophagic and microglial complexity after neuronal injury. Prog Neurobiol 2021;200:101970.
- 42. Kamnaksh A, Kovesdi E, Kwon SK, et al. Factors affecting blast traumatic brain injury. J Neurotrauma 2011;28(10):2145–2153; doi: 10.1089/neu.2011.1983
- 43. Yirmiya R, Rimmerman N, Reshef R.. Depression as a microglial disease. Trends Neurosci 2015;38(10):637–658.
- 44. Kim TD, Lee S, Yoon S. Inflammation in post-traumatic stress disorder (PTSD): a review of potential correlates of PTSD with a neurological perspective. Antioxidants (Basel) 2020;9(2):107.
- 45. Han KM, Ham BJ. How inflammation affects the brain in depression: a review of functional and structural MRI studies. J Clin Neurol 2021;17(4):503–515.
- 46. Li S, Liao Y, Dong Y, et al. Microglial deletion and inhibition alleviate behavior of post-traumatic stress disorder in mice. J Neuroinflammation 2021;18(1):7; doi: 10.1186/s12974-020-02069-9
- 47. Troubat R, Leman S, Pinchaud K, et al. Neuroinflammation and depression: a review. Brain Behav Immun 2021;94:159–174.
- 48. Zheng ZH, Tu JL, Li XH, et al. Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. Brain Behav Immun 2021;91:505–518.
- 49. Ashton JC, Glass M.. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007;5:73–80.
- 50. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas. Glia 2010;58:1017–1030.
- 51. Schomberg D, Olson J.. Immune responses of microglia in the spinal cord: contribution to pain states. Exp Neurol 2012;234:262–270.
- 52. Donat CK, Fischer F, Walter B, et al. Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet. Acta Neurobiol Exp 2014;74:197–210.
- 53. Lunn C, Fine J, Rojas-Triana A, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 2006;316:780–788.
- 54. Lunn C, Reich EP, Fine J, et al. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 2008;153:226–239.
- 55. Liu Y, McAfee SS, Guley NM, et al. Abnormalities in dynamic brain activity caused by mild traumatic brain injury are partially rescued by the cannabinoid type-2 receptor inverse agonist SMM-189. eNeuro 2017;18:4(4):ENEURO.0387-16.2017; doi: 10.1523/ENEURO.0387-16.2017
- 56. Raghava N, Das BC, Ray SK. Neuroprotective effects of estrogen in CNS injuries: insights from animal models. Neurosci Neuroecon 2017;6:15–29.
- 57. Frick KM, Kim J, Tuscher JJ, et al. Sex steroid hormones matter for learning and memory: estrogenic regulation of hippocampal function in male and female rodents. Learn Mem 2015;22:472–493.
- 58. Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Repro Update 2000;6(3):212–224.
- 59. O'Neill K, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004;185(1):63–80.
- 60. Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 2004;150:481–487.
- 61. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–3846.
- 62. Uebelhart B, Herrmann F, Rizzoli R.. Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men. Clin Cases Miner Bone Metab 2009;6:163–168.
- 63. Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 2015;20:685–694.
Associated Data
Data Availability Statement
The data from this present study on raloxifene are available from the investigators upon reasonable request.